Oxford Nanopore & Twist Bioscience Partners to Launch PGx Beta Programme

Oxford Nanopore & Twist Bioscience Partners to Launch PGx Beta Programme

By, Admin 25 May 2024

Oxford Nanopore collaborates with Twist Bioscience to launch PGx Beta Programme and advance personalised medicine

Overview

Oxford Nanopore Technologies (Oxford Nanopore) announced the launch of a new Pharmacogenomics (PGx) Beta Programme to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.  

PGx Solution

The newly unveiled Twist-Oxford Nanopore long-read PGx solution, which is now available for research use, is designed to provide unambiguous genetic results in a single end-to-end workflow from sample to PGx star allele call, alleviating the need for time-consuming and costly follow-up tests in contrast to conventional methods. The beta programme aims to increase the diversity of genetic variants evaluated by Oxford Nanopore’s platform.  

Words from Oxford Nanopore

  • “Our collaboration with Twist Bioscience underscores our commitment to advancing the possibility of personalised medicine through PGx by providing unambiguous genetic results in a single assay,” said Gordon Sanghera, CEO of Oxford Nanopore. 
  • “Combined with Twist’s technology, Oxford Nanopore’s value proposition for PGx lies in the ability to deliver richer data through long reads, ultra-fast sequencing speed, accessible form factor and flexibility in terms of throughput, making it an ideal choice for comprehensive and efficient genetic analysis in clinical settings.""

The CYP2D6 Gene & PGx Beta Programme

  • The PGx beta programme has successfully achieved full resolution of the CYP2D6 gene in a single assay.
  • CYP2D6 is responsible for metabolizing 20% of drugs on the market and is one of the most challenging genes to sequence due to its complex structure. 
  • The Twist Alliance Long-Read PGx Panel coupled with Chinook, Oxford Nanopore’s CYP2D6 -specific allele caller, demonstrated 100% CYP2D6 reference concordance, overcoming the limitations of conventional sequencing technologies.

Key features of the PGx Beta Programme include: 

  • Comprehensive CYP2D6 assay: Achieving full gene resolution in a single test.
  • Integration with Oxford Nanopore devices: Twist’s Library Preparation Reagents and Target Enrichment Panels will be integrated with Oxford Nanopores’ MinION and PromethION flow cells, enabling flexibility in throughput and offering customers a seamless and powerful toolset for Oxford Nanopore sequencing.
  • Continuous innovation and compatibility testing: Ongoing evaluations to ensure combability with Twist’s hybrid capture panels, including exploration of the Twist Alliance Dark Genes Panel and the Twist Exome 2.0, potentially broadening the scope of genetic research and clinical applications.

Words from CEO: Twist Bioscience 

  • “Oxford Nanopore’s technology provides genetic analysis and through our collaboration and the Pharmacogenomics Beta Programme, we’re able to expand the reach of our NGS products and provide researchers with a tool to develop personalised therapies. We’re looking forward to progressing through the Beta Program and exploring additions to our collaboration,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. 
  • “The exceptional uniformity of our sequencer agnostic workflows enables researchers around the world to advance scientific breakthroughs.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!